Provectus Biopharmaceuticals, Inc.
corporate_fare Company Profile
Provectus Biopharmaceuticals, Inc. (OTC:PVCT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for PVCT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for PVCT spans 10-Q, SCHEDULE 13D/A, 8-K, DEF 14A.
Recent high-impact activity:
- Provectus Q3 10-Q: $180,733 Cash, Going Concern Doubt Persists
- Provectus Q2 Loss Narrows 47% but Going Concern Doubt Persists
- CEO Edward Pershing Lifts Stake to 11.61% Through Ongoing Note Conversions
- Provectus Biopharmaceuticals Converts $542.5K Director Fees to Preferred Stock Amid Cash Crunch
- Provectus Biopharmaceuticals Secures U.S. Patent for Novel Light-Independent Eye Drop Targeting Drug-Resistant Ocular Infections
Financial Snapshot
Short Interest & Short Volume
4.57 days to coverFINRA reported short interest of 801,174 shares in PVCT as of the October 30, 2026 settlement, unchanged from the prior period — about 4.6 days to cover at its recent average daily volume. On November 20, 2026, 1.8% of PVCT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for PVCT, detected from its recent SEC filings · based on capital-structure filings through 2026-06-30.
Director Compensation in Stock · Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →